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Development of Vaccines
to Meet Public Health Needs:
Incentives and Obstacles
Philip K Russell*
Introduction: Children's Vaccine Initiative
Experiences with the Children's Vaccine Initiative (CVI) are the
source of many ideas and things I address here. It was an organized
attempt by the international public health community to bring new
technology and a new generation of vaccines into global use. The
initiative was led by the Rockefeller Foundation, and included the
World Health Organization (WHO), the National Vaccine Program
(NVP) and UNICEF. The CVI was initiated because of the
tremendous promise the biotechnology revolution offered in terms of
new vaccines and new ways of immunizing the world. The global
preventive medicine and public health effort is still struggling to control
infectious diseases on a global basis. It has accomplished some
wonderful things - irradication of smallpox, partial irradication of
polio (we'll finish that off by the end of the century, I hope) - but still
many millions of children 'die every year from preventable diseases.
Part of the problem is the difficulty of delivery of vaccines and
vaccines that have a host of deficiencies from the point of view of public
health. The CVI sought to improve the efficiency of vaccination around
the world by (1) building new vaccines that could be given in fewer
doses, (2) immunizing in one or two doses rather than three or four, (3)
including as many antigens as possible into a single combination vaccine
to reduce the burden on the logistical system, (4) expanding the
coverage to include new vaccines that are currently not available on a
global basis, (5) lowering the reactogenicity so that the vaccines are
more acceptable to mothers, children and physicians, (6) giving them
orally, if possible, to lower costs and the dangers and burdens of
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needles and syringes, and (7) improving their heat stability. Heat
stability is an incredibly important asset in the tropical world;
refrigeration needed to get vaccines into villages in the far reaches of
Africa and India has a huge cost. Of course, the bottom line is that the
public health community, doesn't have a lot of money. So affordable
access is an important goal.
These are CVI targets, and there has been a global effort to work
towards them over the past five years. Some progress has been made,
but the combined issues of intellectual property, economics, and
sociology put many obstacles in the way.
It's not just a global issue. The U.S. has its own difficulties in
effectively immunizing its children. Hepatitis B is still not being
universally used, and inactivated polio needs to replace the current oral
polio. Measles still occurs throughout the nation, and as much as 50%
of the population is underimmunized in some inner cities, for example,
because of a fairly cumbersome vaccine schedule. The medical
community would like to see one or two oral combination vaccines to
take care of all vaccine-preventable diseases. Figure 1, below, shows the
incredibly complex 1995 recommended immunization schedule from
the Centers for Disease Control (CDC) - not only complex from the
point of view of the schedule, but omitted explanations of choices go
on for pages!
That schedule is a tremendous burden on the system1 that has to
deliver vaccines to children. This is an expensive schedule to deliver,
and buried in it are vaccines like DTP that are 1950's technology. 'Why
are we still using 1950's technology? Why do we not have combination
vaccines we need and should have? Why haven't we been able to use the
tremendous power and potential of the biotechnology industry and
industrial research to produce new vaccines? The answers are complex
- partly economic, partly regulatory, partly societal and, in this
country, partly governmental incompetence. This complex situation is
going to get much worse before it gets better.
We now have some combined vaccines (DTP and MMR), new
pertussis vaccines being worked on by the National Institutes of Health
1 Also, in the U.S. the system itself is also incredibly complex. It involves state and
city health departments, public health clinics, private practice, HMOs and a whole
spectrum between. And, it's changing as we speak.
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(NIH) are expected within the next year or two. New pneumococcal
vaccines are in the pipeline, a chicken pox vaccine has just been licensed
and hepatitis A is to be added to the schedule. We're going to take an
already cumbersome schedule and add more individual vaccines, and it
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International Vaccine Industry
To understand the problems involved in putting technology to
practical use, one thing to look at is the industry that produces these
vaccines. We rely on the industry for industrial development,
instrument development and production, as well as for quality control.
In the international world, it's about a $3 billion a year industry. It is
dominated by large multinational corporations, such as Merck, Pasteur-
Merieux-Connaught, Biocine-Sclavo, Smith-Kline-Beecham and
Wyeth-Lederle. Many are part of the global programs for vaccination.
Some U.S. companies, for example Merck, have a different
international status than the others because they don't sell vaccines to
UNICEF. The U.S. vaccine industry is separate from European-based
multinationals because of U.S. regulatory and other factors.
Many vaccines are made by big public-sector manufacturers. For
example, Brazil, China, Indonesia and Vietnam largely produce their
own DTP. Yet, they are capable of making only commodity vaccines
using older technologies unencumbered by intellectual property. They
have no capability for developing new products and will depend on
technology transfers from either large multinationals or smaller public-
sector manufacturers. There's a couple of interesting very small public-
sector manufacturers in this country: Michigan Department of Health
and Massachusetts Department of Health, as well as other state
manufacturers and distributors of vaccines. Some smaller countries,
such as Thailand and the Philippines, have small public-sector
manufacturers. And of course, the biotechnology companies are playing
a bigger and bigger role in the international vaccine industry. It's a very
complex industry, and it is a tremendous challenge to bring it up to the
level needed to produce the next generation of vaccines - for southern
as well as northern countries.
Industry and Market Structures Affecting Vaccine Prices
The vaccine market is also complex. Only in the last couple of years
have studies shed some light on how it really works. One aspect of it is
multiple tiers of prices. Large corporate multinational manufacturers
have at least four price levels. They sell at the private retail price
throughout the world wherever they can get licenses for their products.2
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They negotiate prices with their own governments, usually at lower than
private sales prices but still high. They also negotiate prices with
underdeveloped countries that buy vaccines. The bottom tier is very
large volume sales to UNICEF or Pan-American Health Organization
(PAHO). These prices are probably at marginal production costs with
fully amortized facilities and- no royalties. These sales produce only a
modicum of profit, but they are nonetheless important for some
manufacturers. Obviously these are commodity vaccines, selling at
approximately eight cents a dose for polio and ten cents for DTP.
The U.S. domestic market has three tiers. It is protected from the
rest of the world partly by our regulatory system but partly by
established buyer practices. Of course, U.S. manufacturers sell at retail,
the highest prices, with lower negotiated prices for the large heath care
organizations. The third pricing tier is the government contract price,
which has become incredibly contentious in the last two years or so with
respect to the Vaccines for Children program. Because children's
vaccines in the U.S. are no less than 50% of the total vaccine production
and may be as high as 75-80%, this is a very important aspect of the
market dynamic that I discuss in more detail later. It has had a
tremendous impact on the way the vaccine industry invests in new
technology and research.
The vaccine industry is changing dramatically. Vaccine technology
is changing, creating a push from the bottom up to produce new
products. The companies are working rapidly with new combinations
where they can. The use of new adjuvants is a very promising set of
technologies. There is tremendous competition at the technical level
and also tremendous competition at the manufacturing level.
Technologic changes and market changes are driving the companies
into larger and larger aggregates, and there are predictions of maybe
one or two monstrously large vaccine companies in the future. Consider
that Pasteur-Merieux, Lederle and Merck have marketing agreements
with respect to Europe, and that includes Commonwealth Serologic
Laboratory of Canada. Other companies that don't have big marketing
organizations do have other kinds of relationships, like Smith-Kline-
Beecham with MedAmerica and Michigan State Health Lab.
2 One interesting thing is that the private sales market in India is probably the
largest in the world.
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Biotechnology firms are vigorously working to produce new approaches
and are forging impressive new alliances with big companies. They are
driven by technology to share technologies that will produce better
combinations, and they are also driven by marketing considerations.
We're seeing a jump in cost from the commodity vaccines to the new
vaccines which are heavily layered with intellectual property rights. I
think the Hepatitis B vaccine manufactured by Merck and Smith-
Kline-Beecham probably has about 30 associated patents. As we get into
more and more complex combinations, the intellectual property
situation gets much more complex.
The innovations brought about by these changes are very difficult to
transfer to the developing countries; technology transfer is almost a
dirty word in the international health business because of the difficulties
in transferring the technology from either the public or private sector to
developing countries. But because of the cost of vaccines and because of
the nationalistic views of many countries in the underdeveloped world,
the reliance on developing country manufacturing is increasing greatly
and so the world supply of vaccines depends to a very large extent on
manufacturing in developing countries. The international issues of the
management of intellectual property rights and technology transfer are
therefore becoming of ever greater importance.
Vaccine Development and Testing - U.S. Decision-Making
I'd like to turn now to how the U.S. develops, tests and brings
vaccines into use, and to analyze the players and what they do, and how
they contribute to either the progress or the chaos, depending on your
perspective.
At the beginning of development in this country, we depend largely
on the federal government, and to a lesser extent on the private sector,
for basic research. The people who drive that are the individual
investigators, the study sections at the NIH, the reviewers of the grants
and NIH program managers. In the vaccine field, the direction of the
research is driven by the quality of the science and the NIH is driven to
some extent by the disease burden, with medical practitioners taking a
look at this every five years to help it shape its program. That's almost
entirely public-sector support at the basic research level.
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Table 1
Decision-Making in Vaccine Research, Development, Purchase and Use
Stage of RDA Major Decision Makers Basis for Decisions
Basic Research Investigators Scientific interest
Study sections Quality of science
Grant reviewers Disease burden
NIH program managers
Applied Research NIH program managers Feasibility
Disease priorities
Company R&D managers Commercial potential
Patent position





Licensing FDA Safety data
Efficacy data
Utilization ACIP Disease burden
Redbook Committee Efficacy
Effectiveness
Purchase CDCP Congressional action
States Program needs
Price
Private buyers Recommendations of
advisory committees
When you get into applied research, to develop a new product, you
shift to a mixture of NIH program managers and the commercial
sector, the latter coming in with corporate R&D and biotechnology. At
that point, the responsibility for bringing products out of the research
laboratory and into pilot production and testing shifts from the public
to the private sector. Product development is fundamentally a
corporate enterprise in this country. Although the NIH claims to be
developing various vaccines, the fact is that all of the energy and
direction is at the corporate level. The decision-making is driven by the
probability of success, the feasibility of the project, the patent position
and market analysis .- standard commercial considerations that drive
any industry. The user doesn't get any say about what is developed.
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There is no organized structural input into the vaccine industry from
folks who have to use them. Nobody asks those folks.
At the next level of development, responsibility shifts to the Food
and Drug Administration (FDA) to approve the safety and efficacy
data which is produced by the manufacturers. Interestingly, however,
the content of licensing- applications, schedules, and so forth are
controlled by corporations. As licenses are negotiated and discussed,
and until they are finally approved by the FDA, they are confidential.
The rest of the world is shut out. The public sector cannot see what's
going on between the FDA and industry. The FDA has the legal
authority to determine what's on the package insert and the public
recommendations.
Then, committees that deal with vaccine utilization, another
government agency, give the FDA recommendations based on the
scientific data and their views of the importance of the disease and the
vaccine's efficacy. These are the Advisory Committee on Immunization
Practices (ACIP), the Redbook Committee, and the Committee on
Infectious Diseases of the American Panel of Pediatrics - a
professional committee that has traditionally made vaccine
recommendations. They may not agree with the FDA, but they have
no effective way of altering the FDA's decision.
Purchasing decisions shift to another community basically related
to public health. The CDC negotiates the federal contract every two
years for vaccines, based on congressional action which may or not be
rational and which may or may not have any relationship, in fact, to
what public's health needs. The states have to look at the federal health
initiatives, and of course, private buyers must deal with having the
options of only what package other groups have recommended and the
FDA has approved. There's no centralized way of influencing or
planning this, to say nothing of directing it. It's a matter of great
concern to many of us in the vaccine business who come at it from a
public health perspective. For decades, every attempt to systematize
this disjointed system, to bring together into some coherent national
effort the people who bear the responsibility and who have decision-
making authority, has failed.
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As a result, one of the things we see is a difference between what's in
the vaccine development pipeline and what comes out. Figure 2 shows
vaccine development data from the NIH. There's a lot of vaccines in
the basic research stage. Many even get into some sort of Phase I trials
after they get over the scientific and technical barriers. Then, we get
into Phase II and III clinical trials where the availability of resources for
development becomes very dominant. Perhaps the most important
consideration here is the willingness of the private sector to invest in
product development. When private-sector investment has failed, it all
adds up to very few vaccines. We need a coordinated push from
beginning to end. Unless there is vigorous investment from the private
sector, vaccines won't get through the pipeline. That's why we're so
slow in developing the HIV vaccines, that's why we don't have a
malaria vaccine, and that's why many of the vaccines that are beginning
to come out took so long.
Figure 2




Basic Animal Phase I Phase II Phase III Licensed EPI Widespread
Research Models Use
192 173 94 61 42 20 8 6
Why did it take so many years to make the improved pertussis
vaccine? There wasn't enough investment in that, partly because of the
regulatory hurdles for vaccines, with the high levels of safety that have
to be met and proven, and the very high levels of efficacy that have to
be met and proven. The current numbers are maybe between $150 -
't Source: U.S. Government Jordan Report 1994 - does not include HIV vaccine
research, and basic research and animal models are not comprehensive given difficulty
of defining and estimating number of research activities in these early stages.
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$200 million per product for R&D and clinical trial review. I think
those are pretty good estimates. Getting on to vaccine licensing and
distribution and use, there may be a public-sector financing or a social
problem. Although this is not necessarily an U.S. problem, it certainly is
a huge problem in developing countries, especially since new vaccines
come with a much higher price tag than the previous ones.
What are the major obstacles to vaccine development? Market
uncertainties are very high on the list, especially for those vaccines that
will be largely used in public-sector programs. Children's vaccines are
the worst, because there is no authority, no plan, that guides the
industrial investor in which product to develop. The market
uncertainties are exemplified by a tremendous controversy going on
right now in the vaccine industry.
ACIP is considering a shift from the current oral polio vaccine to
the inactivated product. The current oral vaccine has an estimated risk
of one case of paralytic disease per 1 to 2 million individuals vaccinated,
resulting in an average of about eight cases a year in the U.S. That cost
was assumed to be justified because of the risk of importation of polio
in the past. However, currently that risk is dropping because of global
irradication programs. Therefore the burden of those eight cases is
being viewed as unnecessary and untenable, and a matter we ought to
do something about. The problem is that we have to continue with
some use of the oral vaccine to protect the population. There was
insufficient forward planning to develop the intellectual basis on which
to move ahead in a rational manner. The ACIP is threatening to make a
recommendation that is not going to be approved by the FDA.
Manufacturers were not told (or asked) a couple of years ago to
begin studies to get the necessary data for approval. The situation is the
result of a breakdown of our advisory system and our planning system.
It's a fascinating controversy because it contains the history of the
rivalry between Dr. Jonas Salk and Dr. Sabin, and the ethical dilemmas
of the risk to the individual versus the risk to the population and the
rights of the individual versus the public health. It also raises other
questions. Who's in charge of the Federal policy - the FDA or the
CDC? Who's going to win a $100 million - Lederle or Pasteur-
Merieux? And who's got the most muscle in the distribution market?
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It's a raging argument because it extends to many segments of our
population. The industrial folks are going at it, and the academic
people and pediatricians are squaring off against the public health
people. This illustrates that market uncertainty may cause failure to
bring the right products through, and it is related to poor government
planning and coordination.
Government pricing policy poses another obstacle to vaccine
development. In 1993, the fall-out from health care reform was the
Vaccines for Children program that made children's vaccines an
entitlement. Because of the way this program was structured, it was
would raise the level of federal purchases, at negotiated and legally
capped prices, from 50-80% of the market. This caused immediate
dismay in the vaccine industry, multinationals and biotech companies
alike, and a marked diminution of investment in vaccine research. In a
study, Mercer Management estimated that, in large corporations alone,
the detriment to vaccine R&D was $200 million a year, and all from
one decision by Congress. That probably will be fixed this year, but
nobody's quite sure how.
A further obstacle is the high cost of development. This cost is high
because it includes the cost of failures as well as successes, and there is a
high risk of failure. Lack of access to technology is also a critical
obstacle to vaccine development, and therein lies one of our biggest
problems. If I were to design a children's vaccine out of existing
components, I would probably buy the tetanus from one company, the
diphtheria from another, the acellular pertussis components from
another, the hepatitis B from another and the adjuvant from somebody
else. If you want optimal vaccines, you've got to aggregate the material
from all over the place. We don't have the system to do it.
The technology we'd like to aggregate for investment in
combination vaccines is spread among a host of corporations that don't
get together on their own to produce the most optimal combination.
They make deals they can make and know how to make, for their own
reasons. So we're basically stuck with what individual companies come
up with. There is communication between the public sector and the
private sector, between the government agencies involved and the
corporate R&D community, but it's very strained. It's very
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contentious, and it's gotten much worse in the last few years. One of
the things the Disabled Foundation is attempting to do is to develop a
forum for effective communication between the vaccine users,
nutritionists, practitioners, NIH program managers, states and cities,
medical schools, public health systems and advisory groups. That is an
incredibly difficult thing to do, and we do not currently do it very well.
Landmark Legislation Affecting Vaccine Development
I'd like to comment on two very important pieces of legislation that
have influenced the vaccine field dramatically. Public law 99-660 is a
visionary law that set in place the National Vaccine Injury
Compensation Program, which did a tremendous amount to save the
U.S. vaccine industry because it put in place a rational scheme for
compensation for vaccine injury, a system I think is working very well
from everything I've heard and everybody I've talked to. There is an
excise tax on children's vaccines; this money goes into a pot and there is
a commission that adjudicates compensation for children that are
injured. The rationale for compensation has been well worked out, the
system's working and the vaccine companies are shielded to a
reasonable extent from liability and litigation. Another part of that law
was actually an absolute disaster. It put in place a National Vaccine
Program (NVP), with a Program Director named by the Assistant
Secretary of Health who would report directly to the Secretary of
Health and Human Services. That program never worked. It was
supposed to coordinate the activities of the NIH and the CDC with
the FDA and whoever else in the federal government was involved. The
program was supposed to write a national plan, to coordinate in effect
the whole industry. It never worked. The big agency heads were always
more powerful than the guy who was trying to learn something.
The National Vaccine Plan was written by an interagency
committee, but it contained nothing except pabulum. It had no
measures, no muscle and no direction; it just had nice things to say
about each agency. Congress finally repealed the initial program, and
the residual compensation program is now at the CDC for a little
while. It was a gre.at attempt to solve our social problems with getting
the vaccines that we need - and had tremendous unrealized potential.
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I think the other great legislative failure was the Omnibus Budget
Reconciliation Act of 1993 that set in motion the Vaccines for Children
program. It threatened the vaccine industry from an economic point of
view. The program was championed by the administration over the
objection of those like Senator Bumpers who know the vaccine field. It's
had a tremendous impact; I believe that it resulted in a very unfortunate
polarization between the vaccine industry and the government over a
bitterly contentious issue. The concern of the public health community
is that a critical amount, approximately 40-60%, of the vaccine
produced has to be purchased by the public sector and distributed to
folks for whom the cost of the vaccine delivery and active care would
preclude immunization.
Yet, unfortunately, under the Vaccines for Children program, states
were buying vaccines under the federal program and making them
available to the insurance industry. So the vaccine industry wound up
subsidizing the insurance industry. Terrible legislation with a terrible
impact. I'm sure nobody with a hand in that realized what they were
doing. One effort that we're working on now is to get the health care
and the medical insurance industries to ensure the purchase of the
appropriate vaccines within their financial limits. The health care
industry is very willing and is very aggressive is some ways in doing
that; they are beginning to see the benefits. The big health care
organizations do it very vigorously because they see populations that
benefit. The smaller organizations would rather have their patients go to
somebody else for vaccines. In this country we need an appropriate and
cost-effective distribution of vaccine costs between the privatee public
sectors. We do not have that yet.
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Conclusion
Three big issues in developing needed vaccines are: (1) vaccine
production economics per se, (2) the aggregation of intellectual
property required to produce optimal vaccines, and (3) the inability to
plan at the national level.
It might be possible to deal with some of these issues in a
consortium between the vaccine industry and the government -
something like the one used to modernize computer chip
manufacturing. To accomplish this, CEOs of all the big computer
companies had to consider the plan and discuss it in some depth.
However, the cultures of various companies involved with vaccines
are so competitive and so different that this may not be feasible. Large
corporations can't figure out how to work together. Because of this and
the failure of the government to get its act together, the public health
system remains stuck with vaccines that are far below the level that we
could potentially produce.
